<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains susceptible to penicillin and resistant to gentamicin</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains susceptible to penicillin and resistant to gentamicin</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested regimens for therapy of native or prosthetic valve endocarditis due to enterococcal strains susceptible to penicillin and resistant to gentamicin</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2">American Heart Association (AHA)</td> <td class="subtitle1">European Society of Cardiology (ESC)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Adult dose</td> <td class="subtitle2">Pediatric dose</td> <td class="subtitle2">Adult dose</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Aminoglycoside combination regimen<sup>¶</sup></td> <td class="subtitle2_left">Aminoglycoside combination regimen<sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <p>Ampicillin 2 g IV every 4 hours for four to six weeks<sup>Δ</sup></p> <p><strong>or</strong></p> <p>Aqueous penicillin G 18 to 30 million units per 24 hours continuously or in six divided doses for four to six weeks<sup>Δ</sup></p> <p><strong>plus</strong></p> Streptomycin<sup>◊</sup> 15 mg/kg per 24 hours IV or IM in two divided doses for four to six weeks<sup>Δ</sup> </td> <td>Consultation with a pediatric infectious disease expert is recommended in all cases of enterococcal infective endocarditis</td> <td class="indent1"> <p>Amoxicillin 200 mg/kg/day in four to six doses for four to six weeks<sup>Δ</sup></p> <p><strong>or</strong></p> <p>Ampicillin 12 g per day (200 mg/kg per day) in four or six doses for four to six weeks<sup>Δ</sup></p> <p><strong>plus</strong></p> Streptomycin<sup>◊</sup> 15 mg/kg per 24 hours IV or IM in two divided doses for four to six weeks<sup>Δ</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Beta-lactam combination regimen<sup>§</sup></td> </tr> <tr> <td class="indent1"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> Ampicillin 2 g IV every 4 hours for six weeks</td> <td> <p>Ceftriaxone 100 mg/kg per 24 hours IV in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &gt;2 g per 24 hours, use divided dosing every 12 hours) for six weeks</p> <p><strong>plus</strong></p> Ampicillin 200 to 300 mg/kg per 24 hours IV divided in four to six divided doses (maximum dose: 12 g per 24 hours) for six weeks </td> <td class="indent1"> <p>Ceftriaxone 2 g IV every 12 hours for six weeks</p> <p><strong>plus</strong></p> Ampicillin 2 g IV every 4 hours for six weeks</td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class="graphic_footnotes"><p>NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; IV: intravenously; IM: intramuscularly; HLAR: high-level aminoglycoside resistance.</p>
<p>* Patients unable to tolerate beta-lactams should receive treatment as for infection due to isolates with intrinsic penicillin resistance. Refer to UpToDate table on treatment regimens for native or prosthetic valve endocarditis due to an enterococcal strain resistant to penicillin and susceptible to vancomycin and aminoglycosides.</p>
<p>¶ For treatment of infection due to isolates that are gentamicin resistant and streptomycin susceptible (growth inhibited by 1000 mcg/mL) in patients with creatinine clearance &gt;50 mL/minute. Although this regimen was used effectively before gentamicin was established as the preferred aminoglycoside, AHA 2015 guidelines discourage its use. This is because of general lack of physician familiarity with streptomycin, supply shortages, lack of readily available laboratory testing for serum concentration monitoring, and cranial nerve VIII toxicity (refer to text).</p>
<p>Δ Patients with NVE and symptoms &lt;3 months may be treated for 4 weeks; patients with PVE or NVE with symptoms ≥3 months should be treated for at least 6 weeks.</p>
<p>◊ In adults, streptomycin is dosed based on ideal body weight. Dose should be adjusted to obtain serum peak concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.</p>
§ The beta-lactam combination regimen is active against <em>Enterococcus faecalis</em> strains with and without HLAR and is the combination of choice in patients with HLAR <em>E. faecalis</em> endocarditis; it is not bactericidally synergistic against <em>Enterococcus faecium</em>. This regimen is reasonable for patients with normal renal function (and preferred for patients with impaired renal function), abnormal cranial nerve VIII function, and generally in lieu of combination therapy with streptomycin.</div><div class="graphic_reference">Data from:
<ol>
<li>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</li>
<li>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</li>
<li>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</li>
</ol></div><div id="graphicVersion">Graphic 104581 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
